Matching articles for "Patanase"
Issue 1668 · January 23, 2023
Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis

The FDA has approved Ryaltris (Hikma), a fixed-dose combination nasal spray containing the H 1 -antihistamine olopatadine hydrochloride ( Patanase , and generics) and the corticosteroid mometasone furoate (…

Med Lett Drugs Ther. 2023 Jan 23; 65(1668):12-4 doi:10.58347/tml.2023.1668c
The FDA has approved Ryaltris (Hikma), a fixed-dose combination nasal spray containing the H 1 -antihistamine olopatadine hydrochloride ( Patanase , and generics) and the corticosteroid mometasone furoate ( Nasonex 24 HR Allergy , and generics), for treatment of seasonal allergic rhinitis symptoms in persons ≥12 years old. Ryaltris is the second intranasal antihistamine/corticosteroid combination to be approved for this indication; azelastine 0.1%/fluticasone propionate ( Dymista , and generics), which is approved for use in persons ≥6 years old, was the first. Both products are available only by prescription.
Issue 1662 · October 31, 2022 Free
In Brief: OTC Azelastine Nasal Spray 0.15% (Astepro Allergy) for Allergic Rhinitis

The 0.15% nasal spray formulation of the H 1 - antihistamine azelastine hydrochloride ( Astepro Allergy ; Children's Astepro Allergy – Bayer) is now available over the counter (OTC) for temporary relief of…

Med Lett Drugs Ther. 2022 Oct 31; 64(1662):175-6
The 0.15% nasal spray formulation of the H 1 - antihistamine azelastine hydrochloride ( Astepro Allergy ; Children's Astepro Allergy – Bayer) is now available over the counter (OTC) for temporary relief of nasal congestion, runny nose, sneezing, and itchy nose due to allergic rhinitis in adults and children ≥6 years old. It is the first intranasal antihistamine to be approved by the FDA for OTC use. Other drugs that are available OTC for treatment of allergic rhinitis symptoms include oral antihistamines, intranasal corticosteroids, and mast cell stabilizers.
Issue 1622 · April 19, 2021
Drugs for Allergic Rhinitis and Allergic Conjunctivitis

The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).

Med Lett Drugs Ther. 2021 Apr 19; 63(1622):57-64
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Issue 1622 · April 19, 2021
Comparison Table: Some Oral Drugs for Allergic Rhinitis (online only)

View the Comparison Table: Some Oral Drugs for Allergic Rhinitis

Med Lett Drugs Ther. 2021 Apr 19; 63(1622):e63-5
View the Comparison Table: Some Oral Drugs for Allergic Rhinitis
Issue 1622 · April 19, 2021
Comparison Table: Some Nasal Sprays for Allergic Rhinitis (online only)

View the Comparison Table: Some Nasal Sprays for Allergic Rhinitis

Med Lett Drugs Ther. 2021 Apr 19; 63(1622):e66-71
View the Comparison Table: Some Nasal Sprays for Allergic Rhinitis
Issue 1520 · May 8, 2017
Drugs for Allergic Disorders

Allergic rhinitis can be classified as seasonal, perennial, or episodic. It is often associated with allergic conjunctivitis, rhinosinusitis, and asthma. H 1 -ANTIHISTAMINES — Oral – Oral second-generation…

Med Lett Drugs Ther. 2017 May 8; 59(1520):71-82
Allergic rhinitis can be classified as seasonal, perennial, or episodic. It is often associated with allergic conjunctivitis, rhinosinusitis, and asthma. H 1 -ANTIHISTAMINES — Oral – Oral second-generation H 1 -antihistamines are the preferred first-line treatment for relief of the itching, sneezing, and rhinorrhea that characterize mild-to-moderate allergic rhinitis. They are less effective for nasal congestion.
Issue 1520 · May 8, 2017
Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis (online only)

View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis

Med Lett Drugs Ther. 2017 May 8; 59(1520):e85-90
View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis
Issue 129 · May 1, 2013
Drugs for Allergic Disorders

The use of drugs to prevent and control symptoms of allergic disorders can be optimized when patients avoid exposure to specific allergens and/or environmental conditions that trigger or worsen their symptoms.

Treat Guidel Med Lett. 2013 May; 11(129):43-52
The use of drugs to prevent and control symptoms of allergic disorders can be optimized when patients avoid exposure to specific allergens and/or environmental conditions that trigger or worsen their symptoms.
Issue 1402 · October 29, 2012
Azelastine/Fluticasone Propionate (Dymista) for Seasonal Allergic Rhinitis

The FDA has approved a nasal spray fixed-dose combination ( Dymista – Meda) of the H 1 -antihistamine azelastine ( Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate ( Flonase, and…

Med Lett Drugs Ther. 2012 Oct 29; 54(1402):85-7
The FDA has approved a nasal spray fixed-dose combination ( Dymista – Meda) of the H 1 -antihistamine azelastine ( Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate ( Flonase, and generics) for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old who need both medications for symptomatic relief. It is the first nasal spray to be approved in the US that contains both an H 1 -antihistamine and a corticosteroid.
Issue 1310 · April 20, 2009
Azelastine (Astepro) Nasal Spray for Allergic Rhinitis

A new formulation of the H1-antihistamine azelastine hydrochloride 0.1% nasal spray ( Astepro - Meda) has been approved by the FDA for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old…

Med Lett Drugs Ther. 2009 Apr 20; 51(1310):29-30
A new formulation of the H1-antihistamine azelastine hydrochloride 0.1% nasal spray ( Astepro - Meda) has been approved by the FDA for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old and is being heavily advertised to the public on radio, television and the Internet. All azelastine products require a prescription.
Issue 1289 · June 30, 2008
Olopatadine (Patanase) Nasal Spray

Olopatadine 0.6% nasal spray ( Patanase - Alcon) has been approved by the FDA for treatment of seasonal allergic rhinitis in patients ≥ 12 years old. An H1-antihistamine with mast-cell stabilizing activity,…

Med Lett Drugs Ther. 2008 Jun 30; 50(1289):51-2
Olopatadine 0.6% nasal spray ( Patanase - Alcon) has been approved by the FDA for treatment of seasonal allergic rhinitis in patients ≥ 12 years old. An H1-antihistamine with mast-cell stabilizing activity, olopatadine is already marketed for treatment of allergic conjunctivitis in a 0.1% solution as Patanol and in a 0.2% solution as Pataday. Azelastine (Astelin) , another H1-antihistamine with mast-cell stabilizing activity, has been available for intranasal treatment of allergic rhinitis since 1997.